Abivax SA Sees a Surge in Share Price Following a Major Capital Increase

On 2 July 2026, the French biotechnology company Abivax SA, listed on NYSE Euronext Paris, announced that its underwriters had fully exercised the over‑allotment option in a recent equity offering. The additional issuance of American Depositary Shares (ADS) raised the company’s gross proceeds to $920 million (approximately €807 million). This capital injection is earmarked for the commercialization of Obefazimod and the development of new therapeutic candidates, positioning the firm to accelerate its pipeline of antiviral therapies and therapeutic vaccines.

Immediate Market Reaction

The announcement triggered an almost 6 % increase in Abivax’s share price on the day of the news. By the close on 3 July, the stock had climbed 7.7 %, trading at €127.80—a notable rise from the previous day’s close of €121.90. The move lifted the company above its 52‑week high of €132, though the share price still sits well above its 52‑week low of €6.55, underscoring the volatility inherent in biotech equities.

Contextual Factors

The surge came amid a broader rally across European markets. On 3 July, German and Spanish indices hit record highs, while Japanese and South Korean markets rebounded sharply after earlier declines. Singapore’s market also reached new highs. In this favorable environment, Abivax’s performance stood out as a key driver of the positive sentiment in the health‑care sector.

Regulatory developments further bolstered investor confidence. On 2 July, Truist Financial, one of the company’s major institutional shareholders, raised its price target for Abivax to $155 following progress on regulatory approvals for the company’s products. This endorsement underscored the market’s optimism about the company’s pipeline and its ability to translate clinical successes into commercial revenue.

Implications for Investors

The capital raise gives Abivax access to substantial funds without diluting existing shareholders beyond the scope of the over‑allotment exercise. The proceeds will support the commercialization of Obefazimod and the advancement of other candidates such as ABX 464 (Phase II HIV/AIDS), ABX 203 (Phase IIb/III hepatitis B), and ABX 196 (Phase I immune enhancer). Additionally, the company’s ongoing partnerships with French and Cuban research institutes reinforce its research capacity.

For investors, the 7.7 % jump on 3 July represents a tangible return on capital deployed, while the company’s robust pipeline and strategic alliances suggest continued upside potential. However, the historical price volatility—evidenced by a 52‑week low of €6.55—remains a factor to monitor.

All figures are taken from the latest market data and company disclosures as of 3 July 2026. No external analysis beyond the supplied information is included.